Ginkgo Bioworks Holdings, Inc. WT
Get $10 bonus on your first $100 deposit for DNA-WT
Get $10 bonus on your first $100 deposit for DNA-WT
Ginkgo Bioworks Holdings, Inc. WT (DNA-WT) Stock Competitors & Peer Comparison
See (DNA-WT) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
| VRTX | $438.71 | -1.91% | 111.4B | 28.66 | $15.31 | N/A |
| REGN | $761.85 | -1.98% | 79.2B | 18.36 | $41.49 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $746.42 | +0.44% | 46.2B | 38.20 | $19.54 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $318.85 | -3.01% | 42.3B | 136.85 | $2.33 | N/A |
| INSM | $162.43 | -1.47% | 35B | -25.34 | -$6.41 | N/A |
| UTHR | $564.81 | -0.96% | 24.8B | 20.27 | $27.86 | N/A |
| BNTX | $91.18 | +1.97% | 22.9B | -16.76 | -$5.44 | N/A |
Stock Comparison
DNA-WT vs VRTX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, VRTX has a market cap of 111.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while VRTX trades at $438.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas VRTX's P/E ratio is 28.66. In terms of profitability, DNA-WT's ROE is -0.54%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, DNA-WT is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check VRTX's competition here
DNA-WT vs REGN Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, REGN has a market cap of 79.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while REGN trades at $761.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas REGN's P/E ratio is 18.36. In terms of profitability, DNA-WT's ROE is -0.54%, compared to REGN's ROE of +0.15%. Regarding short-term risk, DNA-WT is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check REGN's competition here
DNA-WT vs VRNA Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas VRNA's P/E ratio is -102.80. In terms of profitability, DNA-WT's ROE is -0.54%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, DNA-WT is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check VRNA's competition here
DNA-WT vs ARGX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ARGX has a market cap of 46.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while ARGX trades at $746.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ARGX's P/E ratio is 38.20. In terms of profitability, DNA-WT's ROE is -0.54%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, DNA-WT is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check ARGX's competition here
DNA-WT vs SGEN Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas SGEN's P/E ratio is -57.19. In terms of profitability, DNA-WT's ROE is -0.54%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, DNA-WT is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check SGEN's competition here
DNA-WT vs ALNY Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ALNY has a market cap of 42.3B. Regarding current trading prices, DNA-WT is priced at $0.27, while ALNY trades at $318.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ALNY's P/E ratio is 136.85. In terms of profitability, DNA-WT's ROE is -0.54%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, DNA-WT is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check ALNY's competition here
DNA-WT vs INSM Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, INSM has a market cap of 35B. Regarding current trading prices, DNA-WT is priced at $0.27, while INSM trades at $162.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas INSM's P/E ratio is -25.34. In terms of profitability, DNA-WT's ROE is -0.54%, compared to INSM's ROE of -1.68%. Regarding short-term risk, DNA-WT is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check INSM's competition here
DNA-WT vs UTHR Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, UTHR has a market cap of 24.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while UTHR trades at $564.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas UTHR's P/E ratio is 20.27. In terms of profitability, DNA-WT's ROE is -0.54%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, DNA-WT is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check UTHR's competition here
DNA-WT vs BNTX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, DNA-WT is priced at $0.27, while BNTX trades at $91.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BNTX's P/E ratio is -16.76. In terms of profitability, DNA-WT's ROE is -0.54%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, DNA-WT is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check BNTX's competition here
DNA-WT vs RPRX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RPRX has a market cap of 20.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while RPRX trades at $48.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 27.29. In terms of profitability, DNA-WT's ROE is -0.54%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, DNA-WT is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check RPRX's competition here
DNA-WT vs ROIV Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ROIV has a market cap of 20.3B. Regarding current trading prices, DNA-WT is priced at $0.27, while ROIV trades at $28.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ROIV's P/E ratio is -24.21. In terms of profitability, DNA-WT's ROE is -0.54%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, DNA-WT is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.Check ROIV's competition here
DNA-WT vs BGNE Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BGNE's P/E ratio is -22.55. In terms of profitability, DNA-WT's ROE is -0.54%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, DNA-WT is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check BGNE's competition here
DNA-WT vs RVMD Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RVMD has a market cap of 19.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while RVMD trades at $99.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RVMD's P/E ratio is -16.66. In terms of profitability, DNA-WT's ROE is -0.54%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, DNA-WT is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check RVMD's competition here
DNA-WT vs MRNA Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MRNA has a market cap of 19.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while MRNA trades at $49.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MRNA's P/E ratio is -6.78. In terms of profitability, DNA-WT's ROE is -0.54%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, DNA-WT is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check MRNA's competition here
DNA-WT vs INCY Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, INCY has a market cap of 19.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while INCY trades at $95.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas INCY's P/E ratio is 14.97. In terms of profitability, DNA-WT's ROE is -0.54%, compared to INCY's ROE of +0.29%. Regarding short-term risk, DNA-WT is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check INCY's competition here
DNA-WT vs GMAB Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, GMAB has a market cap of 16.9B. Regarding current trading prices, DNA-WT is priced at $0.27, while GMAB trades at $27.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas GMAB's P/E ratio is 17.86. In terms of profitability, DNA-WT's ROE is -0.54%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, DNA-WT is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check GMAB's competition here
DNA-WT vs SMMT Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, SMMT has a market cap of 14.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while SMMT trades at $19.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas SMMT's P/E ratio is -13.46. In terms of profitability, DNA-WT's ROE is -0.54%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, DNA-WT is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.Check SMMT's competition here
DNA-WT vs BBIO Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BBIO has a market cap of 14.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while BBIO trades at $73.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BBIO's P/E ratio is -19.35. In terms of profitability, DNA-WT's ROE is -0.54%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, DNA-WT is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check BBIO's competition here
DNA-WT vs ASND Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ASND has a market cap of 14.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while ASND trades at $229.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ASND's P/E ratio is -52.58. In terms of profitability, DNA-WT's ROE is -0.54%, compared to ASND's ROE of +1.28%. Regarding short-term risk, DNA-WT is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check ASND's competition here
DNA-WT vs KRTX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas KRTX's P/E ratio is -28.09. In terms of profitability, DNA-WT's ROE is -0.54%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, DNA-WT is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check KRTX's competition here
DNA-WT vs MDGL Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MDGL has a market cap of 12.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while MDGL trades at $546.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MDGL's P/E ratio is -42.56. In terms of profitability, DNA-WT's ROE is -0.54%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, DNA-WT is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check MDGL's competition here
DNA-WT vs IONS Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IONS has a market cap of 12.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while IONS trades at $74.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas IONS's P/E ratio is -31.42. In terms of profitability, DNA-WT's ROE is -0.54%, compared to IONS's ROE of -0.69%. Regarding short-term risk, DNA-WT is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check IONS's competition here
DNA-WT vs EXEL Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, EXEL has a market cap of 11.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while EXEL trades at $43.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas EXEL's P/E ratio is 15.78. In terms of profitability, DNA-WT's ROE is -0.54%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, DNA-WT is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check EXEL's competition here
DNA-WT vs JAZZ Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, JAZZ has a market cap of 11.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while JAZZ trades at $186.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas JAZZ's P/E ratio is -32.01. In terms of profitability, DNA-WT's ROE is -0.54%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, DNA-WT is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check JAZZ's competition here
DNA-WT vs RNAM Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, DNA-WT is priced at $0.27, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RNAM's P/E ratio is -17.39. In terms of profitability, DNA-WT's ROE is -0.54%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, DNA-WT is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check RNAM's competition here
DNA-WT vs BMRN Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BMRN has a market cap of 10.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while BMRN trades at $55.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BMRN's P/E ratio is 30.83. In terms of profitability, DNA-WT's ROE is -0.54%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, DNA-WT is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check BMRN's competition here
DNA-WT vs RXDX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RXDX's P/E ratio is -56.47. In terms of profitability, DNA-WT's ROE is -0.54%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, DNA-WT is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check RXDX's competition here
DNA-WT vs IMGN Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas IMGN's P/E ratio is -111.55. In terms of profitability, DNA-WT's ROE is -0.54%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, DNA-WT is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check IMGN's competition here
DNA-WT vs AXSM Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, AXSM has a market cap of 8.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while AXSM trades at $168.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas AXSM's P/E ratio is -45.79. In terms of profitability, DNA-WT's ROE is -0.54%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, DNA-WT is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check AXSM's competition here
DNA-WT vs ARWR Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ARWR has a market cap of 8.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while ARWR trades at $61.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ARWR's P/E ratio is 38.14. In terms of profitability, DNA-WT's ROE is -0.54%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, DNA-WT is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check ARWR's competition here
DNA-WT vs PCVX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while PCVX trades at $58.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas PCVX's P/E ratio is -10.37. In terms of profitability, DNA-WT's ROE is -0.54%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, DNA-WT is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check PCVX's competition here
DNA-WT vs BPMC Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BPMC's P/E ratio is -51.58. In terms of profitability, DNA-WT's ROE is -0.54%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, DNA-WT is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check BPMC's competition here
DNA-WT vs TECH Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TECH has a market cap of 8.3B. Regarding current trading prices, DNA-WT is priced at $0.27, while TECH trades at $53.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas TECH's P/E ratio is 100.25. In terms of profitability, DNA-WT's ROE is -0.54%, compared to TECH's ROE of +0.04%. Regarding short-term risk, DNA-WT is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.Check TECH's competition here
DNA-WT vs CYTK Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while CYTK trades at $66.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CYTK's P/E ratio is -10.20. In terms of profitability, DNA-WT's ROE is -0.54%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, DNA-WT is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check CYTK's competition here
DNA-WT vs CERE Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CERE's P/E ratio is -16.47. In terms of profitability, DNA-WT's ROE is -0.54%, compared to CERE's ROE of -0.72%. Regarding short-term risk, DNA-WT is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check CERE's competition here
DNA-WT vs ABVX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ABVX has a market cap of 7.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while ABVX trades at $118.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ABVX's P/E ratio is -21.33. In terms of profitability, DNA-WT's ROE is -0.54%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, DNA-WT is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.Check ABVX's competition here
DNA-WT vs NUVL Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, NUVL has a market cap of 7.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while NUVL trades at $105.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas NUVL's P/E ratio is -18.02. In terms of profitability, DNA-WT's ROE is -0.54%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, DNA-WT is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check NUVL's competition here
DNA-WT vs KRYS Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, KRYS has a market cap of 7.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while KRYS trades at $260.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas KRYS's P/E ratio is 38.09. In terms of profitability, DNA-WT's ROE is -0.54%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, DNA-WT is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check KRYS's competition here
DNA-WT vs HALO Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, HALO has a market cap of 7.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while HALO trades at $64.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas HALO's P/E ratio is 25.19. In terms of profitability, DNA-WT's ROE is -0.54%, compared to HALO's ROE of +0.93%. Regarding short-term risk, DNA-WT is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check HALO's competition here
DNA-WT vs IBRX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while IBRX trades at $7.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas IBRX's P/E ratio is -19.21. In terms of profitability, DNA-WT's ROE is -0.54%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, DNA-WT is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.Check IBRX's competition here
DNA-WT vs MTSR Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MTSR's P/E ratio is -23.58. In terms of profitability, DNA-WT's ROE is -0.54%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, DNA-WT is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check MTSR's competition here
DNA-WT vs KYMR Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, KYMR has a market cap of 7B. Regarding current trading prices, DNA-WT is priced at $0.27, while KYMR trades at $85.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas KYMR's P/E ratio is -23.14. In terms of profitability, DNA-WT's ROE is -0.54%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, DNA-WT is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check KYMR's competition here
DNA-WT vs MRUS Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MRUS's P/E ratio is -17.05. In terms of profitability, DNA-WT's ROE is -0.54%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, DNA-WT is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check MRUS's competition here
DNA-WT vs ACLX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while ACLX trades at $114.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ACLX's P/E ratio is -28.20. In terms of profitability, DNA-WT's ROE is -0.54%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, DNA-WT is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check ACLX's competition here
DNA-WT vs BLTE Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, BLTE has a market cap of 6.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while BLTE trades at $169.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas BLTE's P/E ratio is -73.53. In terms of profitability, DNA-WT's ROE is -0.54%, compared to BLTE's ROE of -0.43%. Regarding short-term risk, DNA-WT is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.Check BLTE's competition here
DNA-WT vs PTGX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PTGX has a market cap of 6.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while PTGX trades at $103.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas PTGX's P/E ratio is -50.62. In terms of profitability, DNA-WT's ROE is -0.54%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, DNA-WT is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check PTGX's competition here
DNA-WT vs RETA Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RETA's P/E ratio is -66.29. In terms of profitability, DNA-WT's ROE is -0.54%, compared to RETA's ROE of +0.47%. Regarding short-term risk, DNA-WT is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check RETA's competition here
DNA-WT vs PRAX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PRAX has a market cap of 6.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while PRAX trades at $310.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas PRAX's P/E ratio is -23.04. In terms of profitability, DNA-WT's ROE is -0.54%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, DNA-WT is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check PRAX's competition here
DNA-WT vs RYTM Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, DNA-WT is priced at $0.27, while RYTM trades at $86.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RYTM's P/E ratio is -27.75. In terms of profitability, DNA-WT's ROE is -0.54%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, DNA-WT is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check RYTM's competition here
DNA-WT vs ALKS Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ALKS has a market cap of 5.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while ALKS trades at $34.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ALKS's P/E ratio is 24.36. In terms of profitability, DNA-WT's ROE is -0.54%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, DNA-WT is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check ALKS's competition here
DNA-WT vs SRRK Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while SRRK trades at $50.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas SRRK's P/E ratio is -15.20. In terms of profitability, DNA-WT's ROE is -0.54%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, DNA-WT is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check SRRK's competition here
DNA-WT vs COGT Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while COGT trades at $35.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas COGT's P/E ratio is -16.30. In terms of profitability, DNA-WT's ROE is -0.54%, compared to COGT's ROE of -1.00%. Regarding short-term risk, DNA-WT is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check COGT's competition here
DNA-WT vs CGON Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while CGON trades at $67.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CGON's P/E ratio is -32.44. In terms of profitability, DNA-WT's ROE is -0.54%, compared to CGON's ROE of -0.23%. Regarding short-term risk, DNA-WT is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check CGON's competition here
DNA-WT vs CDTX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CDTX's P/E ratio is -19.77. In terms of profitability, DNA-WT's ROE is -0.54%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, DNA-WT is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check CDTX's competition here
DNA-WT vs PTCT Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while PTCT trades at $67.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas PTCT's P/E ratio is 7.90. In terms of profitability, DNA-WT's ROE is -0.54%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, DNA-WT is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check PTCT's competition here
DNA-WT vs ERAS Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ERAS has a market cap of 5.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while ERAS trades at $17.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ERAS's P/E ratio is -40.48. In terms of profitability, DNA-WT's ROE is -0.54%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, DNA-WT is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.Check ERAS's competition here
DNA-WT vs ABCM Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, DNA-WT's ROE is -0.54%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, DNA-WT is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check ABCM's competition here
DNA-WT vs ISEE Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ISEE's P/E ratio is -22.44. In terms of profitability, DNA-WT's ROE is -0.54%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, DNA-WT is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check ISEE's competition here
DNA-WT vs CAI Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CAI has a market cap of 5.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while CAI trades at $19.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CAI's P/E ratio is -5.99. In terms of profitability, DNA-WT's ROE is -0.54%, compared to CAI's ROE of +0.25%. Regarding short-term risk, DNA-WT is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.Check CAI's competition here
DNA-WT vs CELC Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CELC has a market cap of 5.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while CELC trades at $112.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CELC's P/E ratio is -29.72. In terms of profitability, DNA-WT's ROE is -0.54%, compared to CELC's ROE of -2.03%. Regarding short-term risk, DNA-WT is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check CELC's competition here
DNA-WT vs TGTX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TGTX has a market cap of 5.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while TGTX trades at $33.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas TGTX's P/E ratio is 12.10. In terms of profitability, DNA-WT's ROE is -0.54%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, DNA-WT is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check TGTX's competition here
DNA-WT vs FBIOX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, DNA-WT is priced at $0.27, while FBIOX trades at $25.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas FBIOX's P/E ratio is N/A. In terms of profitability, DNA-WT's ROE is -0.54%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, DNA-WT is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check FBIOX's competition here
DNA-WT vs CNTA Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CNTA has a market cap of 5.3B. Regarding current trading prices, DNA-WT is priced at $0.27, while CNTA trades at $39.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CNTA's P/E ratio is -27.18. In terms of profitability, DNA-WT's ROE is -0.54%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, DNA-WT is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check CNTA's competition here
DNA-WT vs APLS Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while APLS trades at $40.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas APLS's P/E ratio is 224.50. In terms of profitability, DNA-WT's ROE is -0.54%, compared to APLS's ROE of +0.08%. Regarding short-term risk, DNA-WT is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check APLS's competition here
DNA-WT vs IMVT Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IMVT has a market cap of 5B. Regarding current trading prices, DNA-WT is priced at $0.27, while IMVT trades at $24.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas IMVT's P/E ratio is -9.18. In terms of profitability, DNA-WT's ROE is -0.54%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, DNA-WT is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.Check IMVT's competition here
DNA-WT vs CRSP Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while CRSP trades at $49.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CRSP's P/E ratio is -7.65. In terms of profitability, DNA-WT's ROE is -0.54%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, DNA-WT is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check CRSP's competition here
DNA-WT vs TERN Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TERN has a market cap of 4.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while TERN trades at $52.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas TERN's P/E ratio is -51.18. In terms of profitability, DNA-WT's ROE is -0.54%, compared to TERN's ROE of -0.20%. Regarding short-term risk, DNA-WT is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check TERN's competition here
DNA-WT vs MIRM Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MIRM has a market cap of 4.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while MIRM trades at $94.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MIRM's P/E ratio is -200.36. In terms of profitability, DNA-WT's ROE is -0.54%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, DNA-WT is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check MIRM's competition here
DNA-WT vs APGE Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, APGE has a market cap of 4.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while APGE trades at $84.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas APGE's P/E ratio is -19.99. In terms of profitability, DNA-WT's ROE is -0.54%, compared to APGE's ROE of -0.37%. Regarding short-term risk, DNA-WT is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check APGE's competition here
DNA-WT vs FOLD Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while FOLD trades at $14.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas FOLD's P/E ratio is -160.44. In terms of profitability, DNA-WT's ROE is -0.54%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, DNA-WT is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check FOLD's competition here
DNA-WT vs CORT Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CORT has a market cap of 4.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while CORT trades at $42.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 51.82. In terms of profitability, DNA-WT's ROE is -0.54%, compared to CORT's ROE of +0.15%. Regarding short-term risk, DNA-WT is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.Check CORT's competition here
DNA-WT vs AKRO Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas AKRO's P/E ratio is -14.57. In terms of profitability, DNA-WT's ROE is -0.54%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, DNA-WT is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check AKRO's competition here
DNA-WT vs XENE Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, XENE has a market cap of 4.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while XENE trades at $56.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas XENE's P/E ratio is -13.04. In terms of profitability, DNA-WT's ROE is -0.54%, compared to XENE's ROE of -0.56%. Regarding short-term risk, DNA-WT is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check XENE's competition here
DNA-WT vs ALPN Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ALPN's P/E ratio is -101.52. In terms of profitability, DNA-WT's ROE is -0.54%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, DNA-WT is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check ALPN's competition here
DNA-WT vs OPT Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, DNA-WT is priced at $0.27, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas OPT's P/E ratio is -1.52. In terms of profitability, DNA-WT's ROE is -0.54%, compared to OPT's ROE of +0.88%. Regarding short-term risk, DNA-WT is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check OPT's competition here
DNA-WT vs MRTX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas MRTX's P/E ratio is -4.82. In terms of profitability, DNA-WT's ROE is -0.54%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, DNA-WT is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check MRTX's competition here
DNA-WT vs VKTX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, DNA-WT is priced at $0.27, while VKTX trades at $34.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas VKTX's P/E ratio is -10.91. In terms of profitability, DNA-WT's ROE is -0.54%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, DNA-WT is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.Check VKTX's competition here
DNA-WT vs LGND Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, LGND has a market cap of 4B. Regarding current trading prices, DNA-WT is priced at $0.27, while LGND trades at $199.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas LGND's P/E ratio is 32.56. In terms of profitability, DNA-WT's ROE is -0.54%, compared to LGND's ROE of +0.14%. Regarding short-term risk, DNA-WT is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check LGND's competition here
DNA-WT vs CRNX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, DNA-WT is priced at $0.27, while CRNX trades at $37.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CRNX's P/E ratio is -7.52. In terms of profitability, DNA-WT's ROE is -0.54%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, DNA-WT is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check CRNX's competition here
DNA-WT vs NAMS Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, NAMS has a market cap of 3.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while NAMS trades at $32.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas NAMS's P/E ratio is -19.18. In terms of profitability, DNA-WT's ROE is -0.54%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, DNA-WT is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check NAMS's competition here
DNA-WT vs ACAD Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while ACAD trades at $22.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ACAD's P/E ratio is 9.65. In terms of profitability, DNA-WT's ROE is -0.54%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, DNA-WT is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check ACAD's competition here
DNA-WT vs RYZB Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, DNA-WT is priced at $0.27, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas RYZB's P/E ratio is -57.86. In terms of profitability, DNA-WT's ROE is -0.54%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, DNA-WT is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check RYZB's competition here
DNA-WT vs CBAY Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, DNA-WT is priced at $0.27, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CBAY's P/E ratio is -32.81. In terms of profitability, DNA-WT's ROE is -0.54%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, DNA-WT is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check CBAY's competition here
DNA-WT vs KNSA Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, KNSA has a market cap of 3.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while KNSA trades at $48.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 65.09. In terms of profitability, DNA-WT's ROE is -0.54%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, DNA-WT is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check KNSA's competition here
DNA-WT vs EWTX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, EWTX has a market cap of 3.6B. Regarding current trading prices, DNA-WT is priced at $0.27, while EWTX trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas EWTX's P/E ratio is -20.45. In terms of profitability, DNA-WT's ROE is -0.54%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, DNA-WT is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check EWTX's competition here
DNA-WT vs SWTX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas SWTX's P/E ratio is -13.78. In terms of profitability, DNA-WT's ROE is -0.54%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, DNA-WT is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check SWTX's competition here
DNA-WT vs LEGN Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, DNA-WT is priced at $0.27, while LEGN trades at $19.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas LEGN's P/E ratio is -11.81. In terms of profitability, DNA-WT's ROE is -0.54%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, DNA-WT is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check LEGN's competition here
DNA-WT vs LQDA Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, LQDA has a market cap of 3.3B. Regarding current trading prices, DNA-WT is priced at $0.27, while LQDA trades at $37.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is -47.10. In terms of profitability, DNA-WT's ROE is -0.54%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, DNA-WT is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check LQDA's competition here
DNA-WT vs DNTH Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, DNTH has a market cap of 3.3B. Regarding current trading prices, DNA-WT is priced at $0.27, while DNTH trades at $86.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas DNTH's P/E ratio is -20.48. In terms of profitability, DNA-WT's ROE is -0.54%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, DNA-WT is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.Check DNTH's competition here
DNA-WT vs DNLI Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, DNLI has a market cap of 3.3B. Regarding current trading prices, DNA-WT is priced at $0.27, while DNLI trades at $20.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas DNLI's P/E ratio is -6.95. In terms of profitability, DNA-WT's ROE is -0.54%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, DNA-WT is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.Check DNLI's competition here
DNA-WT vs DYN Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, DYN has a market cap of 3.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while DYN trades at $18.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas DYN's P/E ratio is -5.43. In terms of profitability, DNA-WT's ROE is -0.54%, compared to DYN's ROE of -0.61%. Regarding short-term risk, DNA-WT is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.Check DYN's competition here
DNA-WT vs TLX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TLX has a market cap of 3.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while TLX trades at $9.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas TLX's P/E ratio is -456.50. In terms of profitability, DNA-WT's ROE is -0.54%, compared to TLX's ROE of -0.02%. Regarding short-term risk, DNA-WT is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check TLX's competition here
DNA-WT vs GPCR Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, GPCR has a market cap of 3.1B. Regarding current trading prices, DNA-WT is priced at $0.27, while GPCR trades at $53.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas GPCR's P/E ratio is -22.28. In terms of profitability, DNA-WT's ROE is -0.54%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, DNA-WT is less volatile compared to GPCR. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.Check GPCR's competition here
DNA-WT vs CPRX Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, CPRX has a market cap of 3B. Regarding current trading prices, DNA-WT is priced at $0.27, while CPRX trades at $24.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas CPRX's P/E ratio is 14.70. In terms of profitability, DNA-WT's ROE is -0.54%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, DNA-WT is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check CPRX's competition here
DNA-WT vs TARS Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, TARS has a market cap of 3B. Regarding current trading prices, DNA-WT is priced at $0.27, while TARS trades at $70.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas TARS's P/E ratio is -44.10. In terms of profitability, DNA-WT's ROE is -0.54%, compared to TARS's ROE of -0.20%. Regarding short-term risk, DNA-WT is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check TARS's competition here
DNA-WT vs ARQT Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ARQT has a market cap of 2.9B. Regarding current trading prices, DNA-WT is priced at $0.27, while ARQT trades at $23.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ARQT's P/E ratio is -181.77. In terms of profitability, DNA-WT's ROE is -0.54%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, DNA-WT is more volatile compared to ARQT. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check ARQT's competition here
DNA-WT vs VERA Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, VERA has a market cap of 2.9B. Regarding current trading prices, DNA-WT is priced at $0.27, while VERA trades at $40.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas VERA's P/E ratio is -8.77. In terms of profitability, DNA-WT's ROE is -0.54%, compared to VERA's ROE of -0.60%. Regarding short-term risk, DNA-WT is more volatile compared to VERA. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check VERA's competition here
DNA-WT vs ALMS Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, ALMS has a market cap of 2.9B. Regarding current trading prices, DNA-WT is priced at $0.27, while ALMS trades at $23.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas ALMS's P/E ratio is -8.17. In terms of profitability, DNA-WT's ROE is -0.54%, compared to ALMS's ROE of -0.73%. Regarding short-term risk, DNA-WT is less volatile compared to ALMS. This indicates potentially lower risk in terms of short-term price fluctuations for DNA-WT.Check ALMS's competition here
DNA-WT vs IDYA Comparison April 2026
DNA-WT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DNA-WT stands at 18.7B. In comparison, IDYA has a market cap of 2.9B. Regarding current trading prices, DNA-WT is priced at $0.27, while IDYA trades at $32.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DNA-WT currently has a P/E ratio of N/A, whereas IDYA's P/E ratio is -25.58. In terms of profitability, DNA-WT's ROE is -0.54%, compared to IDYA's ROE of -0.11%. Regarding short-term risk, DNA-WT is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for DNA-WT.Check IDYA's competition here